Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegol-Sihematide Dose-Finding Study in Hemodialysis Patients with Anemia
NCT02366325Phase 2Unknown
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jul 2014
- Primary completion
- Dec 2015
- Modality
- PEGylated Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of peglmolesatide in anemia (3 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Percentage of participants who achieved a target hemoglobin response during the study at 24 weeks. Status: unknown.
02
Drugs
peglmolesatide
03
Conditions
anemia
Beyond the preview
Go deeper on NCT02366325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02366325.